Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
Completed
Alcon Research
Phase 4
2008-11-01
The purpose of this study was to assess local nasal adverse effects, as well as systemic
effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3.7 and Patanase
Vehicle, pH 7.0 in patients with perennial allergic rhinitis (PAR).
Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age
Completed
Alcon Research
Phase 2
2008-10-01
The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine
Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2
to less than 6 who have a history of nasal allergies, and to assess the pharmcokinetics
(study of the action of a drug in the body) in these children
Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)
Completed
Glenmark Pharmaceuticals Ltd. India
Phase 2
2014-01-27
A single-center, double-blind, placebo-controlled study of FDC olopatadine hydrochloride and
mometasone furoate nasal spray (Molo; also referred as GSP 301) was conducted in subjects
with seasonal allergic rhinitis. In this study, the efficacy and safety of two regimens (BID
and QD) of the FDC (i.e. Molo 1 and Molo 2) were evaluated compared to placebo nasal spray,
DYMISTA® and PATANASE®.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
